{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-069902","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2026-06-18T13:02:06+00:00","discovered_at":"2026-06-18T13:03:00.196892+00:00","generated_at":"2026-06-18T13:03:20.941936+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki","bullets":["Plans to submit RPDD request to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms.","If RPDD granted and tecarfarin approved, eligible for Priority Review Voucher valued ~$200M (recent sales $180M-$205M).","Dual-track strategy: Global Pharma (CAD-1005, Phase 3-ready for HIT) and Rare Disease (tecarfarin for Kawasaki).","Company to present at BIO International Convention June 22-25, 2026, seeking partnerships.","Kawasaki disease is leading cause of acquired heart disease in children; up to 25% untreated develop CAAs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-069902","json":"https://secwatch.observer/filing/0001213900-26-069902.json","markdown":"https://secwatch.observer/filing/0001213900-26-069902.md","text":"https://secwatch.observer/filing/0001213900-26-069902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026069902/0001213900-26-069902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026069902/ea0295234-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T13:03:20.941936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}